MA29288B1 - Agonistes et antagonistes complets et partiels tres puissants du recepteur de la nociceptine/orphanine fq - Google Patents

Agonistes et antagonistes complets et partiels tres puissants du recepteur de la nociceptine/orphanine fq

Info

Publication number
MA29288B1
MA29288B1 MA30190A MA30190A MA29288B1 MA 29288 B1 MA29288 B1 MA 29288B1 MA 30190 A MA30190 A MA 30190A MA 30190 A MA30190 A MA 30190A MA 29288 B1 MA29288 B1 MA 29288B1
Authority
MA
Morocco
Prior art keywords
orphanine
nociceptin
antagonists
receptor
partial agonists
Prior art date
Application number
MA30190A
Other languages
English (en)
Inventor
Remo Guerrini
Severo Salvadori
Girolamo Calo'
Domenico Regoli
Original Assignee
Ufpeptides S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ufpeptides S R L filed Critical Ufpeptides S R L
Publication of MA29288B1 publication Critical patent/MA29288B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

L'INVENTION CONCERNE DES ANALOGUES DE PEPTIDES DE LA NOCICÉPTINE/ORPHANINE FQ, DES COMPOSITIONS DE CEUX-CI ET L'UTILISATION DE CEUX-CI DANS LE TRAITEMENT DE TROUBLES ET DE DYSFONCTIONNEMENTS RELATIFS À L'ACTIVATION OU AU BLOCAGE DES RÉCEPTEURS NOP.
MA30190A 2005-02-15 2007-08-31 Agonistes et antagonistes complets et partiels tres puissants du recepteur de la nociceptine/orphanine fq MA29288B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000003A ITFE20050003A1 (it) 2005-02-15 2005-02-15 Agonisti pieni e parziali ed antagonisti del recettore per nocicettina/orfanina fq ad elevata potenza.

Publications (1)

Publication Number Publication Date
MA29288B1 true MA29288B1 (fr) 2008-02-01

Family

ID=36685750

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30190A MA29288B1 (fr) 2005-02-15 2007-08-31 Agonistes et antagonistes complets et partiels tres puissants du recepteur de la nociceptine/orphanine fq

Country Status (29)

Country Link
US (1) US8227414B2 (fr)
EP (1) EP1851241B1 (fr)
JP (1) JP5281292B2 (fr)
KR (1) KR101294895B1 (fr)
CN (2) CN104689293A (fr)
AU (1) AU2006215639B2 (fr)
BR (1) BRPI0606998B8 (fr)
CA (1) CA2598121C (fr)
CR (1) CR9379A (fr)
CU (1) CU23823A3 (fr)
CY (1) CY1116456T1 (fr)
DK (1) DK1851241T3 (fr)
EA (1) EA011325B1 (fr)
ES (1) ES2541308T3 (fr)
HR (1) HRP20150731T1 (fr)
HU (1) HUE025000T2 (fr)
IL (1) IL185235A (fr)
IT (1) ITFE20050003A1 (fr)
MA (1) MA29288B1 (fr)
MX (1) MX2007009523A (fr)
NI (1) NI200700205A (fr)
NO (1) NO341856B1 (fr)
PL (1) PL1851241T3 (fr)
PT (1) PT1851241E (fr)
RS (1) RS54095B1 (fr)
SI (1) SI1851241T1 (fr)
UA (1) UA91844C2 (fr)
WO (1) WO2006087340A2 (fr)
ZA (1) ZA200707714B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITNA20090026A1 (it) * 2009-05-14 2010-11-15 Agostino Bruno D Agonisti del recettore nop e loro usi terapeutici
CN112730849B (zh) * 2021-01-14 2023-03-10 山西医科大学第二医院 内源性孤啡肽作为糖尿病合并无症状性心肌缺血的血清生物标志物的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1499888B1 (fr) * 2002-04-29 2010-07-07 Euro-Celtique S.A. Peptides a conformation restreinte se liant au recepteur orl-1
ITMI20022022A1 (it) 2002-09-24 2004-03-25 Girolamo Calo' Analoghi di nocicettina.
ITMI20031349A1 (it) * 2003-07-01 2005-01-02 Ufpeptides S R L Antagonisti del recettore nop e loro usi terapeutici.
CN1634980A (zh) * 2004-10-10 2005-07-06 兰州大学 孤啡肽的类似物

Also Published As

Publication number Publication date
BRPI0606998A2 (pt) 2014-01-21
ITFE20050003A1 (it) 2006-08-16
RS54095B1 (sr) 2015-10-30
ES2541308T3 (es) 2015-07-17
MX2007009523A (es) 2007-09-07
NO20074702L (no) 2007-10-29
WO2006087340A8 (fr) 2007-06-21
CU23823A3 (es) 2012-06-21
DK1851241T3 (en) 2015-06-29
ZA200707714B (en) 2008-06-25
WO2006087340A2 (fr) 2006-08-24
EP1851241B1 (fr) 2015-04-08
JP2008530058A (ja) 2008-08-07
BRPI0606998B1 (pt) 2018-04-10
US8227414B2 (en) 2012-07-24
SI1851241T1 (sl) 2015-08-31
IL185235A (en) 2014-08-31
WO2006087340A3 (fr) 2006-10-26
AU2006215639B2 (en) 2011-05-26
EA011325B1 (ru) 2009-02-27
IL185235A0 (en) 2008-02-09
HRP20150731T1 (hr) 2015-08-14
KR20070119614A (ko) 2007-12-20
CN104689293A (zh) 2015-06-10
BRPI0606998B8 (pt) 2021-05-25
US20100273710A1 (en) 2010-10-28
NO341856B1 (no) 2018-02-12
HUE025000T2 (en) 2016-01-28
EA200701732A1 (ru) 2008-02-28
AU2006215639A1 (en) 2006-08-24
CA2598121C (fr) 2014-11-25
PT1851241E (pt) 2015-08-28
CY1116456T1 (el) 2017-03-15
PL1851241T3 (pl) 2015-09-30
CN101128482A (zh) 2008-02-20
JP5281292B2 (ja) 2013-09-04
EP1851241A2 (fr) 2007-11-07
NI200700205A (es) 2008-06-17
KR101294895B1 (ko) 2013-08-08
UA91844C2 (ru) 2010-09-10
CA2598121A1 (fr) 2006-08-24
CR9379A (es) 2008-04-25

Similar Documents

Publication Publication Date Title
FR24C1011I2 (fr) Diaminopyrimidines utilisees en tant qu'antagonistes de p2x3 et p2x2/3
DE60231868D1 (de) Folat-mimetika und deren folatrezeptorbindende konjugate
MA30128B1 (fr) Combinaisons pharmaceutiques d'un antagoniste de receptuer d'angiotensine et d'un inhibiteur de nep
EP2120938A4 (fr) Analogues de l'imidazopyridine en tant que modulateurs du récepteur de cb2, utilisables pour le traitement de la douleur et des maladies respiratoires et non respiratoires
EP1711165A4 (fr) Proteines d'echafaudage membranaires
ATE490779T1 (de) Y4-selektive rezeptoragonist für therapeutische interventionen
EP1740177A4 (fr) Antagonistes des recepteurs muscariniques de l'acetylcholine
EP1838321A4 (fr) Antagonistes de cxcr4 pour le traitement de l'infection due au vih
EP1850880A4 (fr) Agents therapeutiques a base d'aptameres utiles dans le traitement de troubles lies au complement
EP2150114A4 (fr) Antagonistes des récepteurs de l'oréxine à diazépam à pont oxo
EP1817336A4 (fr) Auristatines comportant une unite d'acide aminobenzoique au n-terminal
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
DZ3209A1 (fr) Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine.
EP1871752A4 (fr) Antagonistes du récepteur de l' orexine de type amidopropoxyphényle
IS8482A (is) Kalsítóníngen-skyldir peptíðviðtaka antagónistar
EP1771188A4 (fr) Methodes et compositions destinees au traitement de l'obesite, de maladies associees a l'insuline et de l'hypercholesterolemie
MA30901B1 (fr) Therapie de combinaison sequentielle
MA29288B1 (fr) Agonistes et antagonistes complets et partiels tres puissants du recepteur de la nociceptine/orphanine fq
FR2857597B1 (fr) Utilisation de conjugues peptidiques pour la preparation de compositions destinees au traitement preventif et curatif de l'alopecie.
ATE457736T1 (de) Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
EP2076285A4 (fr) Antagonistes d'anticorps du récepteur 1 de l'interleukine-13
TW200635919A (en) Novel processes for the preparation of CGRP-receptor antagonists and intermediates thereof
DE602005005476D1 (de) Selektive peptidische agonisten des vpac2-rezeptors
EP1856100A4 (fr) Antagonistes de recepteurs du peptide lie au gene de la calcitonine (cgrp)
MA28602B1 (fr) Pyridin-4-yl-ethynyl-imidazoles et pyrazoles en tant qu'antagonistes des recepteurs mglur5